Public Release: 

Researchers elucidate network of genes that control when puberty begins

Discovery may pave the way for linking environmental factors to early-onset puberty in females

Oregon Health & Science University

PORTLAND, Ore. - In expanding our knowledge of how the brain controls the process of sexual development, researchers at Oregon Healthy & Science University and the University of Pittsburgh have identified for the first time members of an elaborate superfamily of genes that regulate the timing of puberty in highly evolved nonhuman primates. The Zinc finger, or ZNF, gene family comprises approximately 800 individual genes.

A handful of genes in this network, operating within the neuroendocrine brain, serve as a 'neurobiological brake' that delay until the end of childhood the activation of hypothalamic genes responsible for launching puberty, thereby preventing the premature awakening of the process. The paper was published today in the journal Nature Communications.

The paper demonstrates that the ZNF gene family encodes repressors -- proteins that hold in check the activity of genes -- to suppress the launch of puberty. The researchers' fresh insights better position scientists to decipher whether environmental factors push the start of puberty to younger ages. Early puberty is associated with an increased incidence of ovarian, uterine and breast cancer as well as an increased incidence of cardiovascular disease and metabolic diseases.

"Deepening our understanding of how the brain controls the initiation of puberty will allow us to understand why girls are initiating puberty at much earlier ages. This knowledge may help build a foundation for developing new avenues to treat precocious puberty," said Alejandro Lomniczi, Ph.D., lead researcher on the study and assistant scientist in neuroscience at the Oregon National Primate Research Center at OHSU. "Our suspicion is that chemical substances contained in man-made products and other environmental factors, such as nutrition, may accelerate reproductive development by epigenetically antagonizing gene repressors such as ZNFs".

ZNFs exert their inhibitory effect by setting in motion mechanisms that modify gene activity without changing the sequence of DNA. Because of this, the ZNFs are considered to act "epigenetically," that means by conveying to genes information from the environment without changing the genetic code itself.

The researchers found that the abundance of the messenger RNAs encoding GATAD1 and ZNF573, along with that of five other ZNFs, decreases during the juvenile-pubertal transition in nonhuman primates, when the brake on the hypothalamic drive to the pituitary-gonadal axis is released. ZNFs promote the loss of a DNA-associated protein known as 'histone 3 dimethylated at lysine 4' (H3K4me2) from the controlling region of genes that facilitate puberty. H3K4me2 is normally associated with gene activation. Using a gene therapy paradigm and a rodent model, the researchers selectively increased the abundance of GATAD1 or ZNF573 in the hypothalamus of prepubertal female rats and observed that puberty was delayed in these animals. Altogether their findings suggest that as the production of ZNFs decreases in the hypothalamus during late prepubertal development, the "brake" keeping puberty in check is released and sexual maturity begins.


The authors of the paper 'Epigenetic regulation of puberty via Zinc-finger protein-mediated transcriptional repression,' include: Lomniczi, Sergio Ojeda, D.V.M., senior scientist in neuroscience, Hollis Wright, Ph.D., staff scientist in neuroscience, Carlos A Toro, Ph.D., postdoctoral fellow in neuroscience, and Valerie Matagne, staff scientist in neuroscience, all of the Oregon National Primate Research Center, OHSU; Juan Manuel Castellano, Ph.D., postdoctoral fellow in neuroscience, Oregon National Primate Research Center, OHSU, and Department of Cell Biology, Physiology and Immunology, University of Cordoba, CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, and Instituto Maimónides de Investigación Biomédica (IMIBIC)/Hospital Universitario Reina Sofia (HURS); Suresh Ramaswamy, Ph. D, research assistant professor of OB/GYN and reproductive sciences, University of Pittsburgh School of Medicine; and Tony M. Plant, Ph.D, professor of OB/GYN and reproductive sciences, University of Pittsburgh School of Medicine.

This study was supported by grants from the NIH (5RO1 HD013254, U54 HD008610), the U.S. National Science Foundation (NSF: IOS1121691), the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 273034, NIH Training grant T32 HD007133, and NIH Training grant T32 DK00768023.

About OHSU

Oregon Health & Science University is a nationally prominent research university and Oregon's only public academic health center. It serves patients throughout the region with a Level 1 trauma center and nationally recognized Doernbecher Children's Hospital. OHSU operates dental, medical, nursing and pharmacy schools that rank high both in research funding and in meeting the university's social mission. OHSU's Knight Cancer Institute helped pioneer personalized medicine through a discovery that identified how to shut down cells that enable cancer to grow without harming healthy ones. OHSU Brain Institute scientists are nationally recognized for discoveries that have led to a better understanding of Alzheimer's disease and new treatments for Parkinson's disease, multiple sclerosis and stroke. OHSU's Casey Eye Institute is a global leader in ophthalmic imaging, and in clinical trials related to eye disease.


One of seven NIH-supported National Primate Research Centers, the Oregon National Primate Research Center houses more than 30 world-class research programs dedicated to developing research breakthroughs that will lead to cures for human disease and improve patients' quality of life. Its programs span a number of important public health issues, including aging, AIDS, depression, infectious disease, substance abuse, obesity, reproductive health and stem cells. The Center's emphasis on collaborative and clinical translational research helps bring the most advanced ideas into clinical testing. The Center is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.